GPX4 and endometrial cancer: To confirm previously reported findings that mesenchymal-high cancer cells exhibit enhanced sensitivity to GPx4 inhibitors6, we determined the half-maximal inhibitory concentration (IC50) of ML162 in different cell lines, including the NSCLC A549, SCLC DMS53 and DMS273, breast cancer MCF-7 and MDA-MB-231, and endometrial cancer KLE, AN3CA, RL95, Hec50, Hec1A, and Ishikawa cell lines.